Form 4: Sionna Therapeutics Director Joanne L. Viney Acquires Stock Options
SEC Form 4 Filing
Director Joanne L. Viney of Sionna Therapeutics acquired stock options for 39,919 shares of common stock on February 6, 2025.
Summary
- On February 6, 2025, Joanne L. Viney, a director of Sionna Therapeutics, acquired stock options for 39,919 shares of the company's common stock.
- The exercise price of these options is $18.
- The options vest in three equal annual installments starting February 6, 2025, contingent upon continued service.
- The expiration date for these options is February 5, 2035.
- This transaction was reported on February 10, 2025.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard regulatory filing related to stock option grants.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. It provides transparency into insider transactions.
Stakeholder Impact
- Shareholders may view insider transactions as a signal of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 02/06/2025 | Date of stock option grant and first vesting date. |
| 02/05/2035 | Expiration date of the stock options. |
| 02/10/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.